Diamyd Medical AB's revenue per share for the
three
months ended in Feb. 2025 was €0.00.
Diamyd Medical AB's revenue per share for the trailing twelve months (TTM) ended in Feb. 2025 was €0.00.
Warning Sign:
Diamyd Medical AB revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue Per Share Growth Rate of Diamyd Medical AB was -33.30% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was -37.00% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was -33.50% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was -22.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Diamyd Medical AB's Revenue per Share or its related term are showing as below:
FRA:DMN'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -87.3 Med: -25.85 Max: 63
Current: -37
During the past 13 years, Diamyd Medical AB's highest 3-Year average Revenue Per Share Growth Rate was 63.00% per year. The lowest was -87.30% per year. And the median was -25.85% per year.
FRA:DMN's 3-Year Revenue Growth Rate is ranked worse than 84.2% of 791
companies
in the Biotechnology industry
Industry Median: 0.8
vs FRA:DMN: -37.00
Diamyd Medical AB Revenue per Share Historical Data
The historical data trend for Diamyd Medical AB's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Diamyd Medical AB's Revenue per Share
For the Biotechnology subindustry, Diamyd Medical AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diamyd Medical AB's PS Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's PS Ratio distribution charts can be found below:
* The bar in red indicates where Diamyd Medical AB's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Diamyd Medical AB's Revenue Per Share for the fiscal year that ended in Aug. 2024 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Feb. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diamyd Medical AB (FRA:DMN) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Diamyd Medical AB Revenue per Share Related Terms
Thank you for viewing the detailed overview of Diamyd Medical AB's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:DMN has been successfully added to your 